Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB12548 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB12548, RRID:AB_10555048
- Product name
- HPGD polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against HPGD.
- Storage
- Store at 4°C for short term. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
Differential changes in 15-hydroxyprostaglandin dehydrogenase and prostaglandin H synthase (types I and II) in human pregnant myometrium.
Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, DuBois RN
Cancer research 2006 Jul 1;66(13):6649-56
Cancer research 2006 Jul 1;66(13):6649-56
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Ding Y, Tong M, Liu S, Moscow JA, Tai HH
Carcinogenesis 2005 Jan;26(1):65-72
Carcinogenesis 2005 Jan;26(1):65-72
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN
The Journal of biological chemistry 2005 Feb 4;280(5):3217-23
The Journal of biological chemistry 2005 Feb 4;280(5):3217-23
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD
Proceedings of the National Academy of Sciences of the United States of America 2004 Dec 14;101(50):17468-73
Proceedings of the National Academy of Sciences of the United States of America 2004 Dec 14;101(50):17468-73
Differential changes in 15-hydroxyprostaglandin dehydrogenase and prostaglandin H synthase (types I and II) in human pregnant myometrium.
Giannoulias D, Patel FA, Holloway AC, Lye SJ, Tai HH, Challis JR
The Journal of clinical endocrinology and metabolism 2002 Mar;87(3):1345-52
The Journal of clinical endocrinology and metabolism 2002 Mar;87(3):1345-52
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot analysis of HPGD in LoVo whole cell lysates using HPGD polyclonal antibody (Cat # PAB12548). Lane 1 uses a 1 : 6000 dilution. Lane 2 uses a 1 : 1500 dilution.
